4.2 Article

Feline Cardiogenic Arterial Thromboembolism Prevention and Therapy

Journal

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cvsm.2017.05.001

Keywords

Cardiac; Stroke; Cardioembolic; Feline; Cat; Thrombosis

Funding

  1. Bristol-Myers Squibb/Sanofi joint venture
  2. Plavix

Ask authors/readers for more resources

Feline cardiogenic arterial thromboembolism (CATE) is a devastating disease whereby 33% of cats survive their initial event, although approximately 50% of mortality is from euthanasia. Short-term management focuses on inducing a hypocoagulable state, improving blood flow, and providing supportive care. Ideally, all cats should be given 72 hours of treatment to determine the acute clinical course. Preventive protocols include antiplatelet and/or anticoagulant drugs, with the only prospective clinical trial demonstrating that clopidogrel is superior to aspirin with a lower CATE recurrence rate and longer time to recurrent CATE. Newer anticoagulant drugs hold great promise in the future of managing this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available